Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma
F. Stephen Hodi, MD
F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).
The phase I study of nivolumab, which was conducted in 2008, examined the survival outcomes of 107 heavily pretreated patients treated with nivolumab. With the long-term follow-up, Hodi noted there were no new safety signals and no treatment-related deaths. Moreover, 34% of patients remained alive at the 5-year follow-up.
This study's results show that anti–PD-1 therapy can give long-term benefits to patients with advanced melanoma. Hodi is hopeful that this benefit will translate to patients treated with nivolumab with other cancers, as well.